The Huntington's community isn't demanding carte blanche approval for uniQure's drug. They are advocating for an accelerated pathway that grants access to patients who understand the risks, allowing for continued data collection without a five-year sham trial that could make them ineligible for treatment later.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

Market access isn't a launch activity; it's a pre-launch strategy. Its most crucial input is during early clinical trial design, ensuring the right comparators and endpoints are chosen to satisfy payers years down the line. Post-hoc fixes are impossible.

Unlike controlled clinical trial data, real-world evidence is derived from vast, messy, and incomplete data from daily healthcare. This variability is its strength, offering deeper insights into long-term outcomes, drug interactions, and diverse patient populations that clean trial data misses.

While the FDA's primary endpoint for gout drugs is a simple biomarker (uric acid levels), Crystallis designed its Phase 3 trials around harder clinical endpoints like flare reduction. This forward-thinking strategy aims to generate data needed to convince payers of the drug's value, ensuring market access post-approval.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

Individual investigators cannot conduct deeper, meaningful post-hoc analyses without access to patient-level data from original clinical trials. Progress requires collaboration with pharmaceutical manufacturers who hold this data, allowing for more nuanced comparisons beyond initial publications.

Clinicians are pragmatically using novel drug combinations based on safety and early efficacy data from Phase 1b/2 trials like ELEVATE. This practice circumvents the impossibility of running Phase 3 trials for every permutation and is reportedly being covered by insurers, accelerating patient access to new options.

Interpreting early-stage, open-label epilepsy trial data requires nuance. A high seizure reduction percentage confirms a drug is likely effective, but investors should expect a significant drop in that effect size in a placebo-controlled study. The key takeaway is mechanistic validation, not the specific number.